Limits...
Biphasic insulin aspart 30/70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and Basal-bolus therapy.

Heise T, Heinemann L, Hövelmann U, Brauns B, Nosek L, Haahr HL, Olsen KJ - Diabetes Care (2009)

Bottom Line: Study 2: both regimens showed three distinct prandial-related GIR peaks.GIR 24-h area under the curve for BIAsp t.i.d. was higher than for basal-bolus therapy: 2,585.2 vs. 2,289.2 mg/kg.CONCLUSIONS BIAsp had pharmacological advantages over BHI.

View Article: PubMed Central - PubMed

Affiliation: Profil Institut für Stoffwechselforschung, Neuss, Germany. tim.heise@profil-research.de

ABSTRACT
OBJECTIVE Pharmacological profiles of biphasic insulin aspart 30/70 (BIAsp 30) once daily (OD), twice daily (b.i.d.), and three times daily (t.i.d.) were compared with other insulin regimens in two crossover glucose clamp studies of insulin-treated type 2 diabetic patients. RESEARCH DESIGNS AND METHODS Study 1 consisted of BIAsp 30 OD, b.i.d., and t.i.d. versus biphasic human insulin 30/70 (BHI 30), OD (n = 24). Study 2 examined BIAsp 30 t.i.d. versus basal-bolus therapy (insulin glargine OD plus insulin glulisine t.i.d.) (n = 24). Pharmacokinetics/pharmacodynamics (PK/PD) were investigated over 24 h. RESULTS Study 1: PK and PD were markedly different between BIAsp 30 OD and BHI 30 OD: the maximum insulin concentration and glucose infusion rate (GIR) were higher for BIAsp 30; time to maximum metabolism was 1.7 h sooner for BIAsp 30. Study 2: both regimens showed three distinct prandial-related GIR peaks. GIR 24-h area under the curve for BIAsp t.i.d. was higher than for basal-bolus therapy: 2,585.2 vs. 2,289.2 mg/kg. CONCLUSIONS BIAsp had pharmacological advantages over BHI. BIAsp t.i.d. had a similar PD profile to basal-bolus therapy.

Show MeSH

Related in: MedlinePlus

PK and PD profiles following injections of test insulins in two studies in patients with type 2 diabetes, obtained using a euglycemic clamp procedure. A: Study 1: 24-h serum insulin profiles during which patients received BIAsp 30 once (1900 h), twice (0700 and 1900 h), or three times (0700, 1300, and 1900 h) daily, or BHI 30 once daily (1900 h). The 24-h profiles have been overlain for ease of comparison. B: Study 1: 24-h GIR profiles during which patients received BIAsp 30 once (1900 h), twice (0700 and 1900 h), or three times (0700, 1300, and 1900 h) daily, or BHI 30 once daily (1900 h). The 24-h profiles have been overlain for ease of comparison. C: Study 2: 24-h GIR profiles during which patients received BIAsp 30 three times daily (0700, 1300, and 1900 h) or basal-bolus therapy using insulin glargine once daily (2300 h on the day before the clamp and again on the day of the clamp) plus insulin glulisine three times daily (0700, 1300, and 1900 h).
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2713630&req=5

Figure 1: PK and PD profiles following injections of test insulins in two studies in patients with type 2 diabetes, obtained using a euglycemic clamp procedure. A: Study 1: 24-h serum insulin profiles during which patients received BIAsp 30 once (1900 h), twice (0700 and 1900 h), or three times (0700, 1300, and 1900 h) daily, or BHI 30 once daily (1900 h). The 24-h profiles have been overlain for ease of comparison. B: Study 1: 24-h GIR profiles during which patients received BIAsp 30 once (1900 h), twice (0700 and 1900 h), or three times (0700, 1300, and 1900 h) daily, or BHI 30 once daily (1900 h). The 24-h profiles have been overlain for ease of comparison. C: Study 2: 24-h GIR profiles during which patients received BIAsp 30 three times daily (0700, 1300, and 1900 h) or basal-bolus therapy using insulin glargine once daily (2300 h on the day before the clamp and again on the day of the clamp) plus insulin glulisine three times daily (0700, 1300, and 1900 h).

Mentions: The 24-h serum insulin and GIR profiles of BHI 30 OD and BIAsp 30 OD, b.i.d., and t.i.d. showed marked differences (Fig. 1 A and B). Maximum serum insulin concentrations were greater for BIAsp 30 than for BHI 30 (73.1–100.4 mU/l [first injection of each regimen] vs. 46.7 mU/l, respectively). Time to maximum serum insulin concentration was shorter for BIAsp 30 than for BHI 30 (2.1–2.6 h [first injection of each regimen] vs. 3.2 h, respectively). The insulin AUC24h for BIAsp 30 OD was greater than for BHI 30 OD. The AUC24h for the BIAsp 30 regimens reflected total insulin dose: OD (0.6 units/kg) 668.1 ± 191.0 mU · 1−1 · h−1; b.i.d. (1.1 units/kg) 1,123.5 ± 280.0 mU · l−1 · h−1, t.i.d. (1.4 units/kg) 1,405.0 ± 329.7 mU · l−1 · h−1.


Biphasic insulin aspart 30/70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and Basal-bolus therapy.

Heise T, Heinemann L, Hövelmann U, Brauns B, Nosek L, Haahr HL, Olsen KJ - Diabetes Care (2009)

PK and PD profiles following injections of test insulins in two studies in patients with type 2 diabetes, obtained using a euglycemic clamp procedure. A: Study 1: 24-h serum insulin profiles during which patients received BIAsp 30 once (1900 h), twice (0700 and 1900 h), or three times (0700, 1300, and 1900 h) daily, or BHI 30 once daily (1900 h). The 24-h profiles have been overlain for ease of comparison. B: Study 1: 24-h GIR profiles during which patients received BIAsp 30 once (1900 h), twice (0700 and 1900 h), or three times (0700, 1300, and 1900 h) daily, or BHI 30 once daily (1900 h). The 24-h profiles have been overlain for ease of comparison. C: Study 2: 24-h GIR profiles during which patients received BIAsp 30 three times daily (0700, 1300, and 1900 h) or basal-bolus therapy using insulin glargine once daily (2300 h on the day before the clamp and again on the day of the clamp) plus insulin glulisine three times daily (0700, 1300, and 1900 h).
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2713630&req=5

Figure 1: PK and PD profiles following injections of test insulins in two studies in patients with type 2 diabetes, obtained using a euglycemic clamp procedure. A: Study 1: 24-h serum insulin profiles during which patients received BIAsp 30 once (1900 h), twice (0700 and 1900 h), or three times (0700, 1300, and 1900 h) daily, or BHI 30 once daily (1900 h). The 24-h profiles have been overlain for ease of comparison. B: Study 1: 24-h GIR profiles during which patients received BIAsp 30 once (1900 h), twice (0700 and 1900 h), or three times (0700, 1300, and 1900 h) daily, or BHI 30 once daily (1900 h). The 24-h profiles have been overlain for ease of comparison. C: Study 2: 24-h GIR profiles during which patients received BIAsp 30 three times daily (0700, 1300, and 1900 h) or basal-bolus therapy using insulin glargine once daily (2300 h on the day before the clamp and again on the day of the clamp) plus insulin glulisine three times daily (0700, 1300, and 1900 h).
Mentions: The 24-h serum insulin and GIR profiles of BHI 30 OD and BIAsp 30 OD, b.i.d., and t.i.d. showed marked differences (Fig. 1 A and B). Maximum serum insulin concentrations were greater for BIAsp 30 than for BHI 30 (73.1–100.4 mU/l [first injection of each regimen] vs. 46.7 mU/l, respectively). Time to maximum serum insulin concentration was shorter for BIAsp 30 than for BHI 30 (2.1–2.6 h [first injection of each regimen] vs. 3.2 h, respectively). The insulin AUC24h for BIAsp 30 OD was greater than for BHI 30 OD. The AUC24h for the BIAsp 30 regimens reflected total insulin dose: OD (0.6 units/kg) 668.1 ± 191.0 mU · 1−1 · h−1; b.i.d. (1.1 units/kg) 1,123.5 ± 280.0 mU · l−1 · h−1, t.i.d. (1.4 units/kg) 1,405.0 ± 329.7 mU · l−1 · h−1.

Bottom Line: Study 2: both regimens showed three distinct prandial-related GIR peaks.GIR 24-h area under the curve for BIAsp t.i.d. was higher than for basal-bolus therapy: 2,585.2 vs. 2,289.2 mg/kg.CONCLUSIONS BIAsp had pharmacological advantages over BHI.

View Article: PubMed Central - PubMed

Affiliation: Profil Institut für Stoffwechselforschung, Neuss, Germany. tim.heise@profil-research.de

ABSTRACT
OBJECTIVE Pharmacological profiles of biphasic insulin aspart 30/70 (BIAsp 30) once daily (OD), twice daily (b.i.d.), and three times daily (t.i.d.) were compared with other insulin regimens in two crossover glucose clamp studies of insulin-treated type 2 diabetic patients. RESEARCH DESIGNS AND METHODS Study 1 consisted of BIAsp 30 OD, b.i.d., and t.i.d. versus biphasic human insulin 30/70 (BHI 30), OD (n = 24). Study 2 examined BIAsp 30 t.i.d. versus basal-bolus therapy (insulin glargine OD plus insulin glulisine t.i.d.) (n = 24). Pharmacokinetics/pharmacodynamics (PK/PD) were investigated over 24 h. RESULTS Study 1: PK and PD were markedly different between BIAsp 30 OD and BHI 30 OD: the maximum insulin concentration and glucose infusion rate (GIR) were higher for BIAsp 30; time to maximum metabolism was 1.7 h sooner for BIAsp 30. Study 2: both regimens showed three distinct prandial-related GIR peaks. GIR 24-h area under the curve for BIAsp t.i.d. was higher than for basal-bolus therapy: 2,585.2 vs. 2,289.2 mg/kg. CONCLUSIONS BIAsp had pharmacological advantages over BHI. BIAsp t.i.d. had a similar PD profile to basal-bolus therapy.

Show MeSH
Related in: MedlinePlus